The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer.

ABSTRACT: Effective drugs are needed for lung cancer, as this disease remains the leading cause of cancer-related deaths. Rexinoids are promising drug candidates for cancer therapy because of their ability to modulate genes involved in inflammation, cell proliferation or differentiation, and apoptosis through activation of the retinoid X receptor (RXR). The only currently FDA-approved rexinoid, bexarotene, is ineffective as a single agent for treating epithelial cancers and induces hypertriglyceridemia. Here, we used a previously validated screening paradigm to evaluate 23 novel rexinoids for biomarkers related to efficacy and safety. These biomarkers include suppression of inducible nitric oxide synthase (iNOS) and induction of sterol regulatory element-binding protein (SREBP). Because of its poten

SUBMITTER: Moerland JA 

PROVIDER: S-EPMC7746742 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature